Distinct evolution and dynamics of epigenetic and genetic heterogeneity in acute myeloid leukemia

Shan Li, FE Garrett-Bakelman, SS Chung, Mathijs Sanders, T Hricik, F Rapaport, J Patel, R Dillon, P Vijay, AL Brown, AE Perl, J Cannon, L Bullinger, S Luger, M Becker, ID Lewis, LB To, Ruud Delwel, Bob Löwenberg, H DohnerML Guzman, DC Hassane, GJ Roboz, D Grimwade, Peter Valk, RJ D'Andrea, M Carroll, CY (Christopher) Park, D Neuberg, R Levine, AM Melnick, CE Mason

Research output: Contribution to journalArticleAcademicpeer-review

268 Citations (Scopus)


Genetic heterogeneity contributes to clinical outcome and progression of most tumors, but little is known about allelic diveisity for epigenetic compartments, and almost no data exist for acute myeloid leukemia (AML). We examined epigenetic heterogeneity as assessed by cytosine methylation within defined genomic loci with four CpGs (epialleles), somatic mutations, and transcriptomes of AML patient samples at serial time points. We observed that epigenetic allele burden is linked to inferior outcome and varies considerably during disease progression. Epigenetic and genetic allelic burden and patterning followed different patterns and kinetics during disease progression. We observed a subset of AMLs with high epiallele and low somatic mutation burden at diagnosis, a subset with high somatic mutation and lower epiallele burdens at diagnosis, and a subset with a mixed profile, suggesting distinct modes of tumor heterogeneity. Genes linked to promoter-associated epiallele shifts during tumor progression showed increased single-cell transcriptional variance and differential expression, suggesting functional impact on gene regulation. Thus, genetic and epigenetic heterogeneity can occur with distinct kinetics likely to affect the biological and clinical features of tumors.
Original languageUndefined/Unknown
Pages (from-to)792-799
Number of pages8
JournalNature Medicine
Issue number7
Publication statusPublished - 2016

Research programs

  • EMC MM-02-41-03

Cite this